Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin in Parkinson's Disease
NCT04687878Phase 2Completed
- Sponsor
- Dr. Dargahi
- Start
- Jan 2020
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Insulin with Placebo (2 arms). Primary endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III, IV at 12 weeks. Started Jan 2020; status: completed.
02
Drugs
human insulin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04687878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687878.